Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker.

Yen CC, Yeh CN, Cheng CT, Jung SM, Huang SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, Yang CY, Ho CL, Fletcher JA.

Ann Surg Oncol. 2012 Oct;19(11):3491-9. doi: 10.1245/s10434-012-2389-0. Epub 2012 May 17.

PMID:
22588468
2.

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P.

Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Epub 2011 Dec 6. Review.

PMID:
22153892
3.

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP.

Lancet Oncol. 2009 Nov;10(11):1045-52. doi: 10.1016/S1470-2045(09)70242-6. Epub 2009 Sep 28.

4.

Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria.

Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK.

Ann Surg Oncol. 2008 Aug;15(8):2153-63. doi: 10.1245/s10434-008-9969-z. Epub 2008 Jun 11.

PMID:
18546045
5.

Expression level of the mitotic checkpoint protein and G2-M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach.

Fujita A, Yamamoto H, Imamura M, Nakamura N, Maehara Y, Tsuneyoshi M, Oda Y.

Virchows Arch. 2012 Feb;460(2):163-9. doi: 10.1007/s00428-011-1181-z. Epub 2011 Dec 22.

PMID:
22190007
6.

Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.

Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Aurias A, Coindre JM, Debiec-Rychter M, Chibon F.

Clin Cancer Res. 2012 Feb 1;18(3):826-38. doi: 10.1158/1078-0432.CCR-11-1610. Epub 2011 Dec 13.

7.

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors.

Yeh CN, Yen CC, Chen YY, Cheng CT, Huang SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, Chen JS, Yeh TS, Tzeng CH, Chao TC, Fletcher JA.

Oncotarget. 2014 Jun 30;5(12):4071-86.

8.

Subgroups of patients with very large gastrointestinal stromal tumors with distinct prognoses: a multicenter study.

Wada N, Kurokawa Y, Nishida T, Takahashi T, Toyokawa T, Kusanagi H, Hirota S, Tsujinaka T, Mori M, Doki Y.

J Surg Oncol. 2014 Feb;109(2):67-70. doi: 10.1002/jso.23471. Epub 2013 Oct 24.

PMID:
24155204
9.

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.

Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H.

Eur J Surg Oncol. 2011 Oct;37(10):890-6. doi: 10.1016/j.ejso.2011.06.005. Epub 2011 Jul 7.

PMID:
21737227
10.

Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location.

Wei YC, Li CF, Yu SC, Chou FF, Fang FM, Eng HL, Uen YH, Tian YF, Wu JM, Li SH, Huang WW, Li WM, Huang HY.

Mod Pathol. 2009 Oct;22(10):1351-60. doi: 10.1038/modpathol.2009.107. Epub 2009 Jul 31.

11.

Cell cycle proteins predict recurrence in stage II and III colon cancer.

Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann HB, Meijer S, Meijer GA.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S682-92. doi: 10.1245/s10434-012-2216-7. Epub 2012 Feb 4.

PMID:
22311118
12.

Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor.

Yang H, Shen C, Zhang B, Chen H, Chen Z, Chen J.

J Korean Med Sci. 2013 Oct;28(10):1443-8. doi: 10.3346/jkms.2013.28.10.1443. Epub 2013 Sep 25.

13.

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis.

Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Carvalho B, van den Tol MP, Verheul HM, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET group..

Br J Cancer. 2013 Oct 29;109(9):2445-52. doi: 10.1038/bjc.2013.608. Epub 2013 Oct 8.

14.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.

Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

JAMA Oncol. 2015 Sep;1(6):797-805. doi: 10.1001/jamaoncol.2015.2407. Erratum in: JAMA Oncol. 2015 Oct;1(7):989.

PMID:
26204106
15.

Survival analysis of patients with duodenal gastrointestinal stromal tumors.

Miki Y, Kurokawa Y, Hirao M, Fujitani K, Iwasa Y, Mano M, Nakamori S, Tsujinaka T.

J Clin Gastroenterol. 2010 Feb;44(2):97-101. doi: 10.1097/MCG.0b013e3181b8e754.

PMID:
19809358
16.

Surgical therapy for gastrointestinal stromal tumours of the upper gastrointestinal tract.

Das A, Wilson R, Biankin AV, Merrett ND.

J Gastrointest Surg. 2009 Jul;13(7):1220-5. doi: 10.1007/s11605-009-0885-8. Epub 2009 Apr 16.

PMID:
19370382
17.

Aurora kinases as prognostic biomarkers in ovarian carcinoma.

Mendiola M, Barriuso J, Mariño-Enríquez A, Redondo A, Domínguez-Cáceres A, Hernández-Cortés G, Pérez-Fernández E, Sánchez-Navarro I, Vara JA, Suárez A, Espinosa E, González-Barón M, Palacios J, Hardisson D.

Hum Pathol. 2009 May;40(5):631-8. doi: 10.1016/j.humpath.2008.10.011. Epub 2009 Jan 20.

PMID:
19157502
18.

Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.

Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Woźniak A, Limon J, Siedlecki J, Grzesiakowska U, Kakol M, Osuch C, Polkowski M, Głuszek S, Zurawski Z, Ruka W.

Ann Surg Oncol. 2007 Jul;14(7):2018-27. Epub 2007 May 2.

PMID:
17473953
19.

Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases.

Wang M, Xu J, Zhao W, Tu L, Qiu W, Wang C, Shen Y, Liu Q, Cao H.

Med Oncol. 2014 Jan;31(1):819. doi: 10.1007/s12032-013-0819-x. Epub 2013 Dec 14.

PMID:
24338275
20.

SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.

Wang CJ, Zhang ZZ, Xu J, Wang M, Zhao WY, Tu L, Zhuang C, Liu Q, Shen YY, Cao H, Zhang ZG.

World J Gastroenterol. 2015 Jul 21;21(27):8398-407. doi: 10.3748/wjg.v21.i27.8398.

Supplemental Content

Support Center